Polatuzumab vedotin
| Polatuzumab vedotin | |
|---|---|
| Term | Polatuzumab vedotin |
| Short definition | polatuzumab vedotin - (pronounced) (POH-lah-TOO-zoo-mab veh-DOH-tin) A drug used with bendamustine hydrochloride and rituximab to treat adults with diffuse large B-cell lymphoma that has come back or has not improved after treatment with at least two other cancer therapies. It is also being studied in the treatment of other types of cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
polatuzumab vedotin - (pronounced) (POH-lah-TOO-zoo-mab veh-DOH-tin) A drug used with bendamustine hydrochloride and rituximab to treat adults with diffuse large B-cell lymphoma that has come back or has not improved after treatment with at least two other cancer therapies. It is also being studied in the treatment of other types of cancer. Polatuzumab Vedotin contains a monoclonal antibody that attaches to a protein called CD79B, which is found on B cells (a type of white blood cell) and some lymphoma cells. It also contains a cancer drug that can help kill cancer cells. Polatuzumab vedotin is a type of antibody-drug conjugate. Also called Polivy
External links
- Medical encyclopedia article on Polatuzumab vedotin
- Wikipedia's article - Polatuzumab vedotin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski